CYTK Cytokinetics (CYTK) Q2 FY26 earnings call
Cytokinetics delivered a solid second quarter, marked by strong commercial momentum for MYQORZO in the U.S. and its initial European launch in Germany. The company is advancing its pipeline with positive ACACIA-HCM results for aficamten in nonobstructive HCM, informing a planned sNDA submission. This progress, coupled with a fortified balance sheet, positions Cytokinetics for continued global expansion and pipeline investment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CYTK operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Prescribers MYQORZO | 275+In Q1, we saw strong demand with more than 275 unique HCPs prescribing MYQORZO with over 50% from the high-volume CMI writer segment.Source: earnings call transcript | 700+By the end of the quarter, more than 700 unique health care providers in the US have prescribed MYQORZO including approximately 300 physicians from the high-volume CMI writer segment.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.